#United States #Atlanta #Cenobamate #SK Life Science #AES Meeting

New Insights into Cenobamate and Epilepsy

Introduction

In an exciting development for the epilepsy community, SK Life Science, Inc. will present ten posters featuring new data on cenobamate at the upcoming American Epilepsy Society (AES) Annual Meeting, to be held from December 5-9, 2025, in Atlanta, Georgia. SK Life Science, a leader in treatments for central nervous system disorders, emphasizes their commitment to advancing research in epilepsy with these presentations.

The Significance of AES Meeting

The AES Annual Meeting serves as a crucial platform for sharing the latest scientific advancements that can significantly impact the lives of those living with epilepsy. Dr. Sunita Misra, Vice President of Global Clinical Development and Chief Medical Officer at SK Life Science, highlighted the importance of this event, stressing the need for ongoing innovation and improved treatment options in the field.

Overview of Cenobamate

Cenobamate, marketed as XCOPRI®, is an antiseizure medication developed for individuals experiencing uncontrolled seizures. The medication operates through a unique dual mechanism of action, reducing neuronal excitability, which is crucial for the management of epilepsy. Recent studies have shown promising results regarding its efficacy and safety, providing hope for patients who may not respond to existing treatments.

Presentation Details

The posters presented at the AES meeting will explore a variety of topics including:

• - Clinical Efficacy: A look into the effectiveness of cenobamate among different patient populations.
• - Safety Assessments: Insights into the safety profile and side effects related to the medication.
• - Pharmacokinetics: Studies focused on how cenobamate is absorbed, distributed, metabolized, and excreted.
• - Healthcare Resource Utilization: An analysis of how cenobamate affects overall healthcare usage among epilepsy patients.

Key Poster Sessions

1. Poster Session 1 (Saturday, Dec. 6):
- Cenobamate in Adolescent Patients with Focal Epilepsy: A phase 1 pharmacokinetic study.
- Long-Term Efficacy of Adjunctive Cenobamate: Data from a randomized clinical study in an Asian population.
- Mortality Risk After Initiation of Antiseizure Medications: A comparison study featuring cenobamate.

2. Poster Session 2 (Sunday, Dec. 7):
- Late-Breaking Abstract: Efficacy and safety for the treatment of primary generalized tonic-clonic seizures.
- Phase 1 Single-Dose Bioavailability Study of Oral Cenobamate: Insights into the new oral formulation.
- Cenobamate Pharmacokinetic Analyses: A deep dive into adult and elderly focal seizure subjects.

3. Poster Session 3 (Monday, Dec. 8):
- Open-Label Extension of Long-Term Efficacy: Expanded findings on cenobamate's sustained effectiveness.
- Early Response Rates: A review of data from uncontrolled focal seizure patients.

Commitment to Innovation

SK Life Science's investment in research and development reflects their dedication to finding solutions that address the unmet needs in epilepsy care. The data being presented at AES aims not only to share scientific advancements but also to inform and empower medical professionals and patients alike in treatment decisions.

Conclusion

As SK Life Science prepares for the 2025 AES Annual Meeting, the anticipated revelations regarding cenobamate represent a step forward in the quest for improved epilepsy treatments. With nearly 40% of epilepsy patients reporting uncontrolled seizures, discoveries such as those related to cenobamate hold promise for effectively managing this challenging neurological disorder.

For further information on these studies and to access all AES 2025 abstracts, visit SK Life Science's official website.